Maternal administration of busulfan before in utero hematopoietic cell transplantation improves congenic bone marrow cells engraftment in murine model

In utero hematopoietic cell transplantation (IUHCT) is a nonmyeloablative procedure that leads to donor cell chimerism and donor-specific tolerance[1]. IUHCT offers the ability to cure a variety of congenital diseases, including sickle cell disease and thalassemia[2]. Under experiment al conditions, IUHCT has been performed successfully in murine[3,4], sheep[5,6], pig[7,8], dog[9,10] and nonhuman primate models[11,12]. The theoretical advantages of IUHCT (na ïve fetal immune system, potentially expanding hematopoietic niches, and small fetal size) have been used to describe the fetus as the perfect recipient of hematopoietic transplantation[13].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research